Pseudohyperphosphatemia associated with high-dose liposomal amphotericin B therapy
- PMID: 17936740
- PMCID: PMC2128727
- DOI: 10.1016/j.cca.2007.08.008
Pseudohyperphosphatemia associated with high-dose liposomal amphotericin B therapy
Abstract
Background: Acute increases in serum inorganic phosphorus (Pi) up to 4.75 mmol/l in the absence of hypocalcemia and tissue deposition of calcium phosphate were noted in 3 patients receiving liposomal amphotericin B (L-AMB). We investigated L-AMB as a possible cause of pseudohyperphosphatemia.
Methods: Serum samples from the index patient were analyzed for Pi content by our laboratory's primary analyzer (Synchron LX20) and by an alternate analyzer (Vitros). Clear and lipemic serum pools, and normal saline, were spiked with L-AMB and analyzed by the LX20 Pi method. Ultrafiltration studies were performed on patient and spiked sera.
Results: Increased Pi values were obtained only from the LX20 analyzer. There was a direct linear relationship between the concentration of L-AMB in the spiked samples and the LX20 Pi results, indicating a 0.9 mmol/l Pi increase for every 100 mg/l increase in L-AMB. Ultrafiltration normalized the Pi results.
Conclusion: Serum Pi results may be falsely increased in patients receiving L-AMB when measured by the LX20 analyzer. This novel cause of pseudohyperphosphatemia is due to interference of L-AMB with the method and is corrected by ultrafiltration of the specimen. Since the LX20 analyzer is widely used by the clinical laboratories clinicians and laboratory personnel should recognize this interference in order to avoid unnecessary diagnostic procedures and interventions.
Figures


Similar articles
-
Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate.Antimicrob Agents Chemother. 2002 Mar;46(3):834-40. doi: 10.1128/AAC.46.3.834-840.2002. Antimicrob Agents Chemother. 2002. PMID: 11850269 Free PMC article. Clinical Trial.
-
An evaluation of hepatotoxicity and nephrotoxicity of liposomal amphotericin B (L-AMB).J Med Toxicol. 2011 Mar;7(1):12-5. doi: 10.1007/s13181-010-0120-8. J Med Toxicol. 2011. PMID: 21057910 Free PMC article.
-
Pseudohypophosphatemia associated with high-dose liposomal amphotericin B therapy.Clin Biochem. 2017 Nov;50(16-17):967-971. doi: 10.1016/j.clinbiochem.2017.05.016. Epub 2017 May 31. Clin Biochem. 2017. PMID: 28578095
-
The novel lipid delivery system of amphotericin B: drug profile and relevance to clinical practice.Oncol Nurs Forum. 1998 Jan-Feb;25(1):35-48. Oncol Nurs Forum. 1998. PMID: 9460772 Review.
-
Liposomal and lipid-based formulations of amphotericin B.Leukemia. 1996 Jun;10 Suppl 2:s93-6. Leukemia. 1996. PMID: 8649062 Review.
Cited by
-
Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B.Clin Infect Dis. 2019 May 2;68(Suppl 4):S260-S274. doi: 10.1093/cid/ciz076. Clin Infect Dis. 2019. PMID: 31222253 Free PMC article. Review.
-
Case-control study and case series of pseudohyperphosphatemia during exposure to liposomal amphotericin B.Antimicrob Agents Chemother. 2015 Nov;59(11):6816-23. doi: 10.1128/AAC.01306-15. Epub 2015 Aug 17. Antimicrob Agents Chemother. 2015. PMID: 26282423 Free PMC article.
-
Hyperphosphataemia: treatment options.Drugs. 2013 May;73(7):673-88. doi: 10.1007/s40265-013-0054-y. Drugs. 2013. PMID: 23625273 Review.
-
Severe Hyperphosphatemia in a Patient with Mild Acute Kidney Injury.Case Rep Med. 2021 May 10;2021:9962624. doi: 10.1155/2021/9962624. eCollection 2021. Case Rep Med. 2021. PMID: 34046068 Free PMC article.
-
Hyperphosphatemia in an 11-year-old girl with acute myeloid leukemia: Answers.Pediatr Nephrol. 2019 Apr;34(4):627-629. doi: 10.1007/s00467-018-4101-5. Epub 2018 Oct 5. Pediatr Nephrol. 2019. PMID: 30291428 Free PMC article. No abstract available.
References
-
- Adler-Moore J, Proffitt RT. AmBisome: liposomal formulation, structure, mechanism of action, and pre-clinical experience. J Antimicrob Chemother. 2002;49(Suppl S1):21–30. - PubMed
-
- Leenders AC, Daenen S, Jansen RL, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. B J Haematol. 1998;103:205–12. - PubMed
-
- Prentice HG, Hann IM, Herbrecht R, et al. A randomised comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. B J Haematol. 1997;98:711–8. - PubMed
-
- Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med. 1999;340:764–71. - PubMed
-
- Kontoyiannis DP, Andersson BS, Lewis RE, Raad II. Progressive disseminated aspergillosis in a bone marrow transplant recipient: response with a high-dose lipid formulation of amphotericin B. Clin Infect Dis. 2001;32:e94–6. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous